<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743260</url>
  </required_header>
  <id_info>
    <org_study_id>PHENTRA_2015_KPUK</org_study_id>
    <nct_id>NCT02743260</nct_id>
  </id_info>
  <brief_title>Drug Transporter Interaction Study PHENTRA_2015_KPUK</brief_title>
  <official_title>Single Centre in Vivo Cocktail Phenotyping Study on OATP1B1, OCT1/2, MATE1/2K, OAT1/3, and P-gp Drug Transporters in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Umm Al-Qura University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Biomedical and Pharmaceutical Research (IBMP), Nürnberg-Heroldsberg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to contribute to establishing in vivo phenotyping
      procedures for organic anionic transporter polypeptide 1B1 (OATP1B1), organic cation
      transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and
      2,kidney splice variant (MATE1/2K), organic anion transporters 1 and 3 (OAT1/3), and
      p-glycoprotein (P-gp) transporters via a cocktail approach. To this end, marker substrates
      for each of the respective transporters are administered as single doses in one period each
      and as a cocktail in one period to 24 healthy volunteers, and phenotyping metrics are derived
      from plasma and urine concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood sampling: - 0:15 h pre-dose, 0:15, 0:30, 0:45, 1:00, 1:20, 1:40, 2:00, 2:20, 2:40,
      3:00, 3:30, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 24:00 hours post-dose

      Urine Sampling: Pre-dose, 0-4 hours, 4-8 hours, 8-12 hours, 12-16 hours, 16-24 hours

      Drug analysis: by liquid chromatography - tandem mass spectrometry (LC-MS/MS)

      Pharmacokinetic Characteristics: Evaluation is carried out using standard noncompartmental
      characteristics including: area under the plasma concentration vs. time curve truncated at
      time t (AUC0-t), area under the plasma concentration vs. time curve extrapolated to infinity
      (AUC0-∞), peak plasma concentration (Cmax), time of occurrence of Cmax (tmax), apparent
      elimination half-life (t½), clearance over bioavailability (CL/F), renal clearance (CLr) and
      renal secretion. The evaluation may be completed by compartmental population pharmacokinetic
      approaches.

      Statistical evaluation: Pharmacokinetic characteristics are compared for cocktail
      administration vs. individual administration by standard average bioequivalence assessment.

      Safety, tolerability: Adverse events, laboratory and clinical parameters and vital signs will
      be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavailability (CL/F) of pitavastatin</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K): Renal clearance (CLr) of metformin</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>intestinal p-glycoprotein (P-gp): Peak Plasma Concentration (Cmax) of digoxin</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>renal p-glycoprotein (P-gp): Renal clearance (CLr) of digoxin:</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>organic anion transporter 1 (OAT1): Renal clearance (CLr) of adefovir</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>organic anion transporter 3 (OAT3): Renal clearance (CLr) of sitagliptin</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>pitavastatin (OATP1B1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg pitavastatin single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin (MATE1, MATE2K, OCT1, OCT2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg metformin single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>digoxin (intestinal &amp; renal P-glycoprotein)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg digoxin single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adefovir dipivoxil (OAT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg adefovir dipivoxil single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sitagliptin (OAT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg sitagliptin single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cocktail (all substances)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of all individual drugs at respective single doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitavastatin</intervention_name>
    <arm_group_label>pitavastatin (OATP1B1)</arm_group_label>
    <arm_group_label>cocktail (all substances)</arm_group_label>
    <other_name>Livazo®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>metformin (MATE1, MATE2K, OCT1, OCT2)</arm_group_label>
    <arm_group_label>cocktail (all substances)</arm_group_label>
    <other_name>Metformin-CT®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>digoxin</intervention_name>
    <arm_group_label>digoxin (intestinal &amp; renal P-glycoprotein)</arm_group_label>
    <arm_group_label>cocktail (all substances)</arm_group_label>
    <other_name>Digacin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir</intervention_name>
    <arm_group_label>adefovir dipivoxil (OAT1)</arm_group_label>
    <arm_group_label>cocktail (all substances)</arm_group_label>
    <other_name>Hepsera®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <arm_group_label>sitagliptin (OAT3)</arm_group_label>
    <arm_group_label>cocktail (all substances)</arm_group_label>
    <other_name>Januvia®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian

          -  Body mass index (BMI) between and inclusive 18.5 and 30 kg/m2

          -  Willing and capable to confirm written consent prior to enrolment after ample
             information has been provided

          -  Normal findings in the medical history unless the principal investigator considers an
             abnormality to be clinically relevant.

          -  Considered to be healthy by the principal investigator on the basis of extensive
             pre-study screening-

        Exclusion Criteria:

        Standard for healthy volunteers, including:

          -  Female subjects only: positive results in pregnancy test

          -  Female subjects only: lactating women

          -  Female subjects only: subjects who do not use or do not agree to use appropriate
             contraceptive methods during the study as defined in Note for Guidance on Non-Clinical
             Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals
             (CHMP/ICH/286/95 modification)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Fuhr, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacology I, University Hospital Cologne Cologne, NRW, Germany, 50931</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pharmacology I, University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Uwe Fuhr</investigator_full_name>
    <investigator_title>Acting Director, Department of Pharmacology I</investigator_title>
  </responsible_party>
  <keyword>phenotype</keyword>
  <keyword>transporter</keyword>
  <keyword>cocktail</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

